This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients

Stocks in this article: PCYC JNJ ABBV GILD GSK

CHICAGO (TheStreet) -- Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) blood-cancer drug Imbruvica reduced the risk of dying by 57% compared to GlaxoSmithKline's (GSK) Arzerra when used to treat elderly patients with relapsed chronic lymphocytic leukemia, according to results from a phase III study released today at the American Society of Clinical Oncology (ASCO) annual meeting.

Imbruvica was granted accelerated approval by the FDA in February to treat relapsed or refractory chronic lymphocytic leukemia, the most common form of leukemia in adults. The results from the phase III study known as "RESONATE", announced today, will be used by Pharmacyclics and J&J to secure full approval for the drug.

"With ibrutinib, about 80% of patients were still in remission at one year, twice as many as we would expect with standard therapy," said Dr. John Byrd of the Ohio State University Comprehensive Cancer Center and the lead investigator in the RESONATE study, in a statement. [Ibrutinib is the scientific name for Imbruvica.]

In the study, 391 elderly patients with CLL no longer responsive following two or more prior therapies were randomized to treatment with Imbruvica or Arzerra. At a median follow up of 9.4 months, Imbruvica was associated with an 57% lower risk of dying (hazard ratio 0.43) and an 80% reduction in the risk of tumor progression (hazard ratio 0.21) compared to Arzerra. Median overall survival and median progression-free survival have not been reached for Imbruvica.

Forty-two percent of patients responded to Imbruvica compared to 4% of Arzerra patients.

Diarrhea, minor bleeding and atrial fibrillation were side effects more commonly reported in the Imbruvica arm of the study, while Arzerra patients reported higher rates of peripheral neuropahthy. The study investigators note kidney problems reported in patients from a prior Imbruvica studies were not apparent in the RESONATE study. 

Imbruvica faces competition for CLL patients from still-experimental drugs being developed by Abbvie (ABBV) and Gilead Sciences (GILD). Both companies will also be presenting new clinical data at this year's ASCO meeting. 



Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,574.57 +217.70 1.25%
S&P 500 2,034.30 +21.41 1.06%
NASDAQ 4,697.1520 +52.84 1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs